Plasma Long Non-Coding RNA RP11-438N5.3 Level for Non-Small Cell Lung Cancer Diagnosis [Letter]

• Main Authors: Yang CQ, Zhang GM
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-04-01
• Series: Cancer Management and Research
• Subjects: long non-coding rna; biomarker; non-small cell lung cancer; rp11-438n5.3
• Online Access: https://www.dovepress.com/plasma-long-non-coding-rna-rp11-438n53-level-for-non-small-cell-lung-c-peer-reviewed-article-CMAR

Chun-Qiu Yang, 1 Guo-Ming Zhang 2 1Department of Laboratory Medicine, Taihe County People’s Hospital, Fuyang 236600, People’s Republic of China; 2Department of Laboratory Medicine, Shuyang People’s Hospital, Shuyang Hospital Affiliated to Xuzhou Medical University, Shuyang 223600, People’s Republic of ChinaCorrespondence: Guo-Ming ZhangDepartment of Laboratory Medicine, Shuyang People’s Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Shuyang 223600, People’s Republic of ChinaEmail [e-mail] Chen et al 1 published an article entitled “Plasma Long Non-Coding RNA RP11-438N5.3 as a Novel Biomarker for Non-Small Cell Lung Cancer” in the Cancer Management and Research journal. To evaluate the diagnostic efficiency of Plasma level of RP11-438N5.3 for non-small-cell lung cancer (NCLC), the investigators enrolled  69 NCLC patients and 69 healthy controls in this study. Plasma level of RP11-438N5.3 was determined using quantitative reverse transcription PCR (qRT-PCR), and receiver operating characteristic (ROC) curve analysis was assessed to determine the diagnostic performance of Plasma level of RP11-438N5.3 level in NCLC. They found that Plasma level of RP11-438N5.3 level was significantly lower in NCLC patients than healthy controls and the area under ROC curve (AUC) is  0.814. Therefore, they concluded that the Plasma level of RP11-438N5.3 was a novel diagnostic biomarker for NCLC. View the original paper by Chen and colleagues